How does 0NZU's PB Ratio compare to its peers?

0NZU is good value based on its Price-To-Book Ratio (5.4x) compared to the peer average (7.1x).

How does 0NZU's PB Ratio compare vs other companies in the GB Biotechs Industry?

0NZU is expensive based on its Price-To-Book Ratio (5.4x) compared to the UK Biotechs industry average (2.8x).

What is 0NZU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0NZU's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 0NZU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0NZU (DKK679) is trading above our estimate of [[fair value]] (DKK167.43)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Zealand Pharma (LSE:0NZU) - Stock Price, News & Analysis

0NZU Stock Overview

A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. More details

0NZU fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings are forecast to grow 65.84% per year

Analysts in good agreement that stock price will rise by 50.6%

Risk Analysis

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Zealand Pharma A/S Competitors

Genus

LSE:GNS

UK£1.1b

Oxford Biomedica

LSE:OXB

UK£432.0m

Bioventix

AIM:BVXP

UK£195.7m

Avacta Group

AIM:AVCT

UK£165.4m

Price History & Performance

Summary of all time highs, changes and price drops for Zealand Pharma
Historical stock prices
Current Share Price	DKK 679.00
52 Week High	DKK 969.00
52 Week Low	DKK 311.20
Beta	0.54
11 Month Change	-14.30%
3 Month Change	-26.37%
1 Year Change	116.10%
33 Year Change	358.82%
5 Year Change	220.13%
Change since IPO	913.43%

Recent updates

Shareholder Returns

	0NZU	GB Biotechs	GB Market
7D	-22.3%	-6.0%	-0.3%
1Y	116.1%	-22.4%	6.1%

Return vs Industry: 0NZU exceeded the UK Biotechs industry which returned -21.1% over the past year.

Return vs Market: 0NZU exceeded the UK Market which returned 5.6% over the past year.

Price Volatility

Is 0NZU's price volatile compared to industry and market?
0NZU volatility
0NZU Average Weekly Movement	6.3%
Biotechs Industry Average Movement	9.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0NZU has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0NZU's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	298	Adam Steensberg	www.zealandpharma.com

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Zealand Pharma A/S Fundamentals Summary

How do Zealand Pharma's earnings and revenue compare to its market cap?
0NZU fundamental statistics
Market cap	DKK 47.79b
Earnings (TTM)	-DKK 1.05b
Revenue (TTM)	DKK 76.87m

621.7x

P/S Ratio

-45.4x

P/E Ratio

Is 0NZU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0NZU income statement (TTM)
Revenue	DKK 76.87m
Cost of Revenue	DKK 704.13m
Gross Profit	-DKK 627.26m
Other Expenses	DKK 425.28m
Earnings	-DKK 1.05b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 20, 2025

Earnings per share (EPS)	-14.90
Gross Margin	-816.00%
Net Profit Margin	-1,369.25%
Debt/Equity Ratio	3.2%

How did 0NZU perform over the long term?

See historical performance and comparison

0NZU Stock Overview

Rewards

Risk Analysis

Zealand Pharma A/S Competitors

LSE:GNS

UK£1.1b

LSE:OXB

UK£432.0m

AIM:BVXP

UK£195.7m

AIM:AVCT

UK£165.4m

Price History & Performance

Recent News & Updates

Employee Representative Director recently sold kr.1.3m worth of stock

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Third quarter 2024 earnings released: kr.3.77 loss per share (vs kr.1.27 profit in 3Q 2023)

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Recent updates

Employee Representative Director recently sold kr.1.3m worth of stock

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Third quarter 2024 earnings released: kr.3.77 loss per share (vs kr.1.27 profit in 3Q 2023)

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Insufficient new directors

President & CEO recently sold kr.31m worth of stock

Second quarter 2024 earnings released: kr.4.67 loss per share (vs kr.5.50 loss in 2Q 2023)

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings released: kr.4.19 loss per share (vs kr.5.77 loss in 1Q 2021)

Insufficient new directors

Zealand Pharma Announces CEO Changes

Full year 2021 earnings: Revenues in line with analyst expectations

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

First quarter 2021 earnings released: kr.5.78 loss per share (vs kr.4.98 loss in 1Q 2020)

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes